February 22, 2024
Immunotherapies such as CAR T-cell therapy hold a lot of promise in treating illnesses like cancer. However, key challenges remain in their development, in particular the need to address adverse events and patient resistance.
In this webcast, Dr. Carl June, a pioneer in the field of CAR T-cell therapy, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on developing immuno- and CAR T-cell therapies.
Key topics discussed in this cell therapy focused webcast:
- Academic and Industry Partnership in CAR-T Development
- CAR-T Development in US and China
- Biomarkers from vein to vein: Mechanism, Selection, and Resistance
- Facing the Challenges: Adverse Events and Patient Resistance
- New Frontiers: Solid Tumors, Evolutionary and Revolutionary CAR models
Dr. Carl June
Dr. June is a member of CellCarta’s Scientific Advisory Board and the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.
In 2011, his research team published a paper on the first CAR-T therapy treating leukemia patients with their own genetically modified T-cells.
Mr. Christopher Ung
Mr. Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field.
Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumour and anatomic pathology services.